Nasal drug administration: Potential for targeted central nervous system delivery

Journal of Pharmaceutical Sciences

Volumn 94, Issue 6, 2005, Pages 1187-1195

  Graff, Candace L ^a   Pollack, Gary M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Blood brain barrier; Brain; Central nervous system; Nasal delivery

Indexed keywords

ALUMINUM; ANGIOTENSIN; ARGIPRESSIN; CADMIUM; CEFALEXIN; COCAINE; DOPAMINE; GLYCOPROTEIN P; INSULIN; LOPERAMIDE; MANGANESE; NICKEL; RIFAMPICIN; SULFONAMIDE; VERAPAMIL; ZIDOVUDINE;

ANTINOCICEPTION; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DOSE RESPONSE; DRUG DELIVERY SYSTEM; ENCEPHALITIS VIRUS; HEPATITIS VIRUS; HERPES SIMPLEX VIRUS; HUMAN; NONHUMAN; NOSE MUCOSA; OLFACTORY EPITHELIUM; OLFACTORY NERVE; PROTEIN EXPRESSION; RABIES; SHORT SURVEY; STREPTOCOCCUS PNEUMONIAE;

EID: 21344453274     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20318     Document Type: Review

References (51)

1. Graff CL, Pollack GM. 2004. Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab 5(1):95-108.
2. Johnson MD, Chen J, Anderson BD. 2002. Investigation of the mechanism of enhancement of central nervous system delivery of 2′-beta-fluoro-2′, 3′-dideoxyinosine via a blood-brain barrier adenosine deaminase-activated prodrug. Drug Metab Dispos 30(2):191-198.
3. Savolainen J, Edwards JE, Morgan ME, McNamara PJ, Anderson BD. 2002. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. Drug Metab Dispos 30(5):479-482.
4. Erdlenbruch B, Alipour M, Fricker G, Miller DS, Kugler W, Eibl H, Lakomek M. 2003. Alkylglycerol opening of the blood-brain barrier to small and large: fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharmacol 140(7):1201-1210.
5. Dahlin M, Bergman U, Jansson B, Bjork E, Brittebo E. 2000. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res 17(6):737-742.
6. Graff CL, Pollack GM. 2003. P-glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm Res 20(8):1225-1230.
7. Minn A, Leclerc S, Heydel JM, Minn AL, Denizcot C, Cattarelli M, Netter P, Gradinaru D. 2002. Drug transport into the mammalian brain: The nasal pathway and its specific metabolic barrier. J Drug Target 10(4):285-296.
8. Hussain AA, Kimura R, Huang CH. 1984. Nasal absorption of testosterone in rats. J Pharm Sci 73(9):1300-1301.
9. Evans J, Hastings L. 1992. Accumulation of Cd(II) in the CNS depending on the route of administration: Intraperitoneal, intratracheal, or intranasal. Fundam Appl Toxicol 19(2):275-278.
10. Perlman S, Sun N, Barnett EM. 1995. Spread of MHV-JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes. Adv Exp Med Biol 380:73-78.
11. Thorne RG, Emory CR, Ala TA, Frey WH, II. 1995. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 692(1-2):278-282.
12. Illum L. 2000. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11(1):1-18.
13. Chow HH, Anavy N, Villalobos A. 2001. Direct nose-brain transport of benzoylecgonine following intranasal administration in rats. J Pharm Sci 90(11):1729-1735.
14. Mathison S, Nagilla R, Kompella UB. 1998. Nasal route for direct delivery of solutes to the central nervous system: Fact or fiction? J Drug Target 5(6):415-441.
15. Chow HS, Chen Z, Matsuura GT. 1999. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci 88(8):754-758.
16. Enting RH, Hoetelmans RM, Lange JM, Burger DM, Beijnen JH, Portegies P. 1998. Antiretroviral drugs and the central nervous system. Aids 12(15):1941-1955.
17. Banks WA, During MJ, Niehoff ML. 2004. Brain uptake of the glucagon-like Peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther 309(2):469-475.
18. Sakane T, Akizuki M, Yamashita S, Nadai T, Hashida M, Sezaki H. 1991. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: The relation to the lipophilicity of the drug. Chem Pharm Bull (Tokyo) 39(9):2456-2458.
19. Seki T, Sato N, Hasegawa T, Kawaguchi T, Juni K. 1994. Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats. Biol Pharm Bull 17(8):1135-1137.
20. Hilger OA. 1989. Applied anatomy and physiology of the nose. In: Adams GL, Boles LR, Hilger PA, editors. Boles's Fundamentals of Otolaryngology, ed., Philadelphia: W.B. Saunders. pp 177-195.
21. Nolte J. 1988. The human brain, ed., St. Louis: C.V. Mosby Co.
22. Graziadei PPC, Monti-Graziadei GA. 1985. Neurogenesis and plasticity of the olfactory sensory nurons. Ann NY Acad Sci 457:127-145.
23. Jackson RT, Tigges J, Arnold W. 1979. Subarachnoid space of the CNS, nasal mucosa, and lymphatic system. Arch Otolaryngol 105:180-184.
24. Erlich SS, McComb JG, Hyman S, Weiss MH. 1986. Ultrastructural morphology of the olfactory pathway for cerebrospinal fluid drainage in the rabbit. J Neurosurg 64:466-473.
25. Pietrowsky R, Struben C, Molle M, Fehm HL, Born J. 1996. Brain potential changes after intranasal vs. intravenous administration of vasopressin: Evidence for a direct nose-brain pathway for peptide effects in humans. Biol Psychiatry 39(5):332-340.
26. Derad I, Willeke K, Pietrowsky R, Born J, Fehm HL. 1998. Intranasal angiotensin II directly influences central nervous regulation of blood pressure. Am J Hypertens 11(8 Pt. 1):971-977.
27. Kern W, Born J, Schreiber H, Fehm HL. 1999. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 48(3):557-563.
28. Gu J, Zhang QY, Center MB, Lipinskas TW, Negishi M, Nebert DW, Ding X. 1998. Purification and characterization of heterologously expressed mouse CYP2A5 and CYP2G1: Role in metabolic activation of acetaminophen and 2,6-dichlorobenzonitrile in mouse olfactory mucosal microsomes. J Pharmacol Exp Ther 285(3):1287-1295.
29. Giorgi M, Marini S, Longo V, Mazzaccaro A, Amato G, Gervasi PG. 2000. Cytochrome P450-dependent monooxygenase activities and their inducibility by classic P450 inducers in the liver, kidney, and nasal mucosa of male adult ring-necked pheasants. Toxicol Appl Pharmacol 167(3):237-245.
30. Bond JA, Harkema JR, Russell VI. 1988. Regional distribution of xenobiotic metabolizing enzymes in respiratory airways of dogs. Drug Metab Dispos 16(1):116-124.
31. Gervasi PG, Longo V, Naldi F, Panattoni G, Ursino F. 1991. Xenobiotic-metabolizing enzymes in human respiratory nasal mucosa. Biochem Pharmacol 41(2):177-184.
32. Wioland MA, Fleury-Feith J, Corlieu P, Commo F, Monceaux G, Lacau-St-Guily J, Bernaudin JF. 2000. CFTR, MDR1, and MRP1 immunolocalization in normal human nasal respiratory mucosa. J Histochem Cytochem 48(9):1215-1222.
33. Kandimalla KK, Donovan MD. 2003. Carrier mediated transport of small molecules across bovine olfactory mucosa: Implications in nose to brain transport. AAPS Pharm Sci Vol. 5, No. 4, Abstract T3140.
34. Gross EA, Swenberg JA, Fields S, Popp JA. 1982. Comparative morphometry of the nasal cavity in rats and mice. J Anat 135(Pt. 1):83-88.
35. Schreider J. 1986. Comparative anatomy and function of the nasal passages. In: Barrow CS, editor Toxicology of the nasal passages, ed., Washington: Hemisphere Publishing Corporation, pp 1-25.
36. Davson H, Welch K, Segal MB. 1987. Secretion of cerebrospinal fluid. The Physiology and Pathophysiology of the Cerebrospinal Fluid, ed., London: Churchill Livingstone. p 201.
37. Dahlin M, Jansson B, Bjork E, Bergman U, Brittebo E. 2001. Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci 14(1):75-80.
38. Dagenais C, Graff CL, Pollack GM. 2004. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67(2):269-276.
39. Terasaki T, Pardridge WM. 2000. Targeted drug delivery to the brain (blood-brain barrier, efflux, endothelium, biological transport). J Drug Target 8(6):353-355.
40. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. 2001. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21(7):778-796.
41. Dantzig AH, de Alwis DP, Burgess M, Law KL, Cao J, Starling JJ. 2003. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 55(1):133-150.
42. Sharom FJ. 1997. The P-glycoprotein efflux pump: How does it transport drugs? J Membr Biol 160(3):161-175.
43. Perl DP, Good PF. 1987. Uptake of aluminium into central nervous system along nasal-olfactory pathways. Lancet 1(8540):1028.
44. Brenneman KA, Wong BA, Buccellato MA, Costa ER, Gross EA, Dorman DC. 2000. Direct olfactory transport of inhaled manganese ((54)MnCl(2)) to the rat brain: Toxicokinetic investigations in a unilateral nasal occlusion model. Toxicol Appl Pharmacol 169(3):238-248.
45. Henriksson J, Tallkvist J, Tjalve H. 1997. Uptake of nickel into the brain via olfactory neurons in rats. Toxicol Lett 91(2):153-162.
46. Sakane T, Akizuki M, Yamashita S, Sezaki H, Nadai T. 1994. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: The relation to the dissociation of the drug. J Pharm Pharmacol 46(5):378-379.
47. Beers DR, Henkel JS, Schaefer DC, Rose JW, Strciop WG. 1993. Neuropathology of herpes simplex virus encephalitis in a rat seizure model. J Neuropathol Exp Neurol 52(3):241-252.
48. Perlman S, Barnett E, Jacobsen G. 1993. Mouse hepatitis virus and herpes simplex virus move along different CNS pathways. Adv Exp Med Biol 342:313-318.
49. Astic L, Saucier D, Coulon P, Lafay F, Flamand A. 1993. The CVS strain of rabies virus as transneuronal tracer in the olfactory system of mice. Brain Res 619(1-2):146-156.
50. Rake G. 1937. The rapid invasion of the body through the olfactory mucosa. J Exp Med 65:303-315.
51. Dahlin M, Bergman U, Jansson B, Bjork E, Brittebo E. 2000. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res 17(6):737-742.